These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20970188)

  • 1. Cardiotoxicity of imatinib: At the heart of the problem.
    Tiribelli M; Medeot M
    Leuk Res; 2011 Jan; 35(1):36-7. PubMed ID: 20970188
    [No Abstract]   [Full Text] [Related]  

  • 2. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Rosti G; Martinelli G; Baccarani M
    Nat Med; 2007 Jan; 13(1):15; author reply 15-6. PubMed ID: 17206121
    [No Abstract]   [Full Text] [Related]  

  • 3. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Atallah E; Kantarjian H; Cortes J
    Nat Med; 2007 Jan; 13(1):14; author reply 15-6. PubMed ID: 17206119
    [No Abstract]   [Full Text] [Related]  

  • 4. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Hatfield A; Owen S; Pilot PR
    Nat Med; 2007 Jan; 13(1):13; author reply 15-6. PubMed ID: 17206118
    [No Abstract]   [Full Text] [Related]  

  • 5. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Gambacorti-Passerini C; Tornaghi L; Franceschino A; Piazza R; Corneo G; Pogliani E
    Nat Med; 2007 Jan; 13(1):13-4; author reply 15-6. PubMed ID: 17206117
    [No Abstract]   [Full Text] [Related]  

  • 6. [Management of chronic myeloid leukemia by imatinib].
    Kizaki M
    Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
    Mcpherson T; Sherman V; Turner R
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V; Vakalopoulou S; Tziomalos K
    Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A
    Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract]   [Full Text] [Related]  

  • 10. Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib.
    Meng HT; Li Y; Jin J; Qian WB; Yang CM
    Ann Hematol; 2007 Mar; 86(3):231-2. PubMed ID: 17123082
    [No Abstract]   [Full Text] [Related]  

  • 11. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
    Shimizu K; Kuroda H; Kida M; Watanabe H; Shirao S; Akiyama T; Fujimi A; Tanaka I; Sato T; Matsunaga T; Niitsu Y
    Rinsho Ketsueki; 2005 Oct; 46(10):1152-5. PubMed ID: 16440780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA approves Gleevec for pediatric leukemia.
    FDA Consum; 2003; 37(4):6. PubMed ID: 12971334
    [No Abstract]   [Full Text] [Related]  

  • 14. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
    Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
    Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
    [No Abstract]   [Full Text] [Related]  

  • 15. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases.
    Breccia M; Cannella L; Montefusco E; Frustaci A; Pacilli M; Alimena G
    Leuk Res; 2008 Mar; 32(3):519-20. PubMed ID: 17804066
    [No Abstract]   [Full Text] [Related]  

  • 16. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
    Cashen A; DiPersio JF; Khoury H
    J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
    [No Abstract]   [Full Text] [Related]  

  • 17. Peripheral neuropathy as an adverse effect of imatinib therapy.
    Chakupurakal G; Etti RJ; Murray JA
    J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
    [No Abstract]   [Full Text] [Related]  

  • 18. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
    Breccia M; Alimena G
    Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
    [No Abstract]   [Full Text] [Related]  

  • 19. STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia.
    Kumar L; Kumari M; Menon H
    Natl Med J India; 2002; 15(5):298. PubMed ID: 12502149
    [No Abstract]   [Full Text] [Related]  

  • 20. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
    Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
    Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.